AllSight
Companies · ALKS · Pharmaceutical Preparations

Alkermes plc. (ALKS)

Alkermes plc. (ALKS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Alkermes plc. (ALKS) stock — financials & valuation

Key numbers for Alkermes plc. (ALKS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 43/100 — a percentile rank of Alkermes plc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$6.8B
P / E102.8×
P / S4.1×
EV / EBITDA37.9×
Gross margin84.6%
Operating margin7.0%
Net margin4.0%
Return on equity3.7%
ROIC2.8%
Revenue growth10.8%
Debt / equity0.8×
Dividend yield0.0%

Is Alkermes plc. overvalued? P/E looks overvalued vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from Alkermes plc.’s own financial statements and shown as context, never as advice.

Sep 16, 2026Board appointment
Alkermes adds Anne Whitaker to board as $600,000 equity award quietly follows
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact